These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3943269)

  • 1. Nalmefene: intravenous safety and kinetics of a new opioid antagonist.
    Dixon R; Howes J; Gentile J; Hsu HB; Hsiao J; Garg D; Weidler D; Meyer M; Tuttle R
    Clin Pharmacol Ther; 1986 Jan; 39(1):49-53. PubMed ID: 3943269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.
    Dixon R; Gentile J; Hsu HB; Hsiao J; Howes J; Garg D; Weidler D
    J Clin Pharmacol; 1987 Mar; 27(3):233-9. PubMed ID: 3680580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.
    Matzke GR; Frye RF; Alexander AC; Reynolds R; Dixon R; Johnston J; Rault RM
    J Clin Pharmacol; 1996 Feb; 36(2):144-51. PubMed ID: 8852390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study.
    Rosen DA; Morris JL; Rosen KR; Nelson ER; Steelman RJ; Gustafson RA; Wilhelm JA; Chang CT; Thackara JW; Frye RF
    Pharmacotherapy; 2000 Jul; 20(7):745-9. PubMed ID: 10907964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged blockade of opioid effect with oral nalmefene.
    Gal TJ; DiFazio CA; Dixon R
    Clin Pharmacol Ther; 1986 Nov; 40(5):537-42. PubMed ID: 3533370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of the opioid antagonist, nalmefene, in rat and dog.
    Murthy SS; Mathur C; Kvalo LT; Lessor RA; Wilhelm JA
    Xenobiotica; 1996 Jul; 26(7):779-92. PubMed ID: 8819305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nalmefene: radioimmunoassay for a new opioid antagonist.
    Dixon R; Hsiao J; Taaffe W; Hahn E; Tuttle R
    J Pharm Sci; 1984 Nov; 73(11):1645-6. PubMed ID: 6520774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Jallad NS; Wilhelm JA; Bikhazi GB
    Br J Clin Pharmacol; 1996 Sep; 42(3):301-6. PubMed ID: 8877019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.
    Geer EB; Landman RE; Wardlaw SL; Conwell IM; Freda PU
    Pituitary; 2005; 8(2):115-22. PubMed ID: 16379031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
    Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J
    Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
    Turncliff R; DiPetrillo L; Silverman B; Ehrich E
    Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
    Liao RF; Zeng ZP; Wen YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1816-9. PubMed ID: 18971181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.
    Grant JE; Potenza MN; Hollander E; Cunningham-Williams R; Nurminen T; Smits G; Kallio A
    Am J Psychiatry; 2006 Feb; 163(2):303-12. PubMed ID: 16449486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
    Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
    Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nalmefene: quantitation of a new narcotic antagonist in human plasma using high performance-liquid chromatography with electrochemical detection.
    Hsiao J; Dixon R
    Res Commun Chem Pathol Pharmacol; 1983 Dec; 42(3):449-54. PubMed ID: 6665302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.